Replace The HumansAI agents & platforms, verified

Paige

AI foundation models for cancer diagnostics, including FDA-cleared Paige Prostate and Breakthrough Device-designated PanCancer Detect for multi-tissue cancer variant identification; acquired by Tempus.

Acquiredmedium confidenceVerified 2026-08-01

This is where the depth lives — everything below is evidence-graded

How the product is positioned

AI foundation models for cancer diagnostics, including FDA-cleared Paige Prostate and Breakthrough Device-designated PanCancer Detect for multi-tissue cancer variant identification; acquired by Tempus

Our summary of the vendor’s positioning — verbatim claim not yet recorded

What we found

Level 2 · augmentative

Completes the unit of work end to end without a person producing it, but a radiologist must sign the report; FDA clearances in this category are for assistive use. That checkpoint is imposed from outside the product, not configured within it.

The human checkpoint here is imposed by regulation — it is not a setting that can be turned off.

Graded 2026-08-01 · re-check 2026-11-01

Procurement detail

Deployment
saasvendor documentation
Compliance
HIPAA · FDA-cleared (Paige Prostate) · FDA Breakthrough Device Designation (PanCancer Detect)report dates not disclosed — request before signing
Integrations
Digital pathology scanners claim unverifiedlab information systems claim unverifiedTempus platform claim unverified
Pricing
platform-licenseNot publicly listed.
Human checkpoint
Requiredregulatory, not configurable
Named customers
Academic medical centers and cancer labs (not individually named)from cited sources

Will they still be here?

Acquired
Funding
Acquired by Tempus AI (NASDAQ: TEM); previously raised $241M over 8 rounds
Founded
2018
HQ
New York, USA
Ownership
Acquired by Tempus AI (NASDAQ: TEM); previously raised $241M over 8 rounds

Sources

Logo retrieved 2026-08-01from the vendor’s own site · trademark of Tempus AI, Inc. (formerly Paige.AI)

  • paige.aiVendor-published · retrieved 2026-08-01
  • tracxn.comIndependent · retrieved 2026-08-01

Where it’s weak

Now part of Tempus, so its future is tied to Tempus's diagnostics/data business priorities.

Corrections

Vendors may submit factual corrections free of charge. We correct facts and publish the change. We do not accept payment to change a grade. Submit a correction →